Cytogen Stock Fundamentals
| 217330 Stock | KRW 4,330 70.00 1.64% |
Cytogen fundamentals help investors to digest information that contributes to Cytogen's financial success or failures. It also enables traders to predict the movement of Cytogen Stock. The fundamental analysis module provides a way to measure Cytogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytogen stock.
Cytogen |
Cytogen Company Shares Outstanding Analysis
Cytogen's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cytogen Shares Outstanding | 5.63 M |
Most of Cytogen's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytogen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Cytogen has 5.63 M of shares currently outstending. This is 96.88% lower than that of the Healthcare sector and significantly higher than that of the Biotechnology & Medical Research industry. The shares outstanding for all Republic of Korea stocks is 99.01% higher than that of the company.
Cytogen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cytogen's current stock value. Our valuation model uses many indicators to compare Cytogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cytogen competition to find correlations between indicators driving Cytogen's intrinsic value. More Info.Cytogen is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytogen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytogen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Did you try this?
Run AI Portfolio Architect Now
AI Portfolio ArchitectUse AI to generate optimal portfolios and find profitable investment opportunities |
| All Next | Launch Module |
Cytogen Fundamentals
| Return On Equity | -96.72 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (9.92) % | |||
| Current Valuation | 324.23 B | |||
| Shares Outstanding | 5.63 M | |||
| Shares Owned By Insiders | 39.37 % | |||
| Shares Owned By Institutions | 0.05 % | |||
| Price To Sales | 487.61 X | |||
| Revenue | 347.85 M | |||
| Gross Profit | (129.63 M) | |||
| EBITDA | (5.87 B) | |||
| Net Income | (10.87 B) | |||
| Cash And Equivalents | 30.29 B | |||
| Total Debt | 20.9 B | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 16.09 X | |||
| Cash Flow From Operations | (5.23 B) | |||
| Beta | 1.16 | |||
| Market Capitalization | 95.89 B | |||
| Total Asset | 55.53 B | |||
| Z Score | 2.4 | |||
| Net Asset | 55.53 B |
About Cytogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Cytogen, Inc., a biotechnology company, develops and sells CTC enrichment and downstream systems to treat cancer in South Korea. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea. Cytogen is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with Cytogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytogen will appreciate offsetting losses from the drop in the long position's value.Moving against Cytogen Stock
The ability to find closely correlated positions to Cytogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytogen to buy it.
The correlation of Cytogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytogen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cytogen Stock
Cytogen financial ratios help investors to determine whether Cytogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cytogen with respect to the benefits of owning Cytogen security.